The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.
Advertisment
The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.